CG
RIGL icon

Caprock Group’s Rigel Pharmaceuticals RIGL Stock Holding History

Caprock Group’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$239K Buy
+6,105
New +$188K ﹤0.01% 1105
2026
Q1 		– Sell
-7,405
Closed -$317K – 1267
2025
Q4 		$317K Buy
+7,405
New +$279K 0.01% 979
2020
Q1 		– Sell
-1,960
Closed -$42K – 410
2019
Q4 		$42K Buy
+1,960
New +$40.4K 0.01% 364

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caprock Group's RIGL Position: Q2 2026 in Review

Caprock Group opened a new position in Rigel Pharmaceuticals (RIGL) in Q2 2026: 6,105 shares worth $239K. The stake represents ﹤0.01% of the portfolio and ranks #1105 among its holdings. This is a return to the name: Caprock Group previously reported a position in RIGL as recently as Q4 2025.

Caprock Group first reported a position in RIGL in Q4 2019 and has held it in 3 quarters since. The position peaked at $317K in Q4 2025. 156 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • Caprock Group held 6,105 shares of Rigel Pharmaceuticals worth $239K as of Q2 2026.
  • Rigel Pharmaceuticals was a new Caprock Group position in Q2 2026.
  • Rigel Pharmaceuticals made up ﹤0.01% of Caprock Group's portfolio in Q2 2026, its #1105 holding.
  • Caprock Group first reported a position in Rigel Pharmaceuticals in Q4 2019 and has held it in 3 quarters since.
  • Caprock Group's Rigel Pharmaceuticals position peaked at $317K in Q4 2025.
  • 156 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on Caprock Group's 13F filing for Q2 2026, filed 27 Jul 2026.